Your browser doesn't support javascript.
The characteristics of COVID-19 vaccine-related headache: Clues gathered from the healthcare personnel in the pandemic.
Ekizoglu, Esme; Gezegen, Hasim; Yalinay Dikmen, Pinar; Orhan, Elif Kocasoy; Ertas, Mustafa; Baykan, Betül.
  • Ekizoglu E; Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey.
  • Gezegen H; Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey.
  • Yalinay Dikmen P; Acibadem Mehmet Ali Aydinlar University School of Medicine, Department of Neurology, Istanbul, Turkey.
  • Orhan EK; Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey.
  • Ertas M; Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey.
  • Baykan B; Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey.
Cephalalgia ; 42(4-5): 366-375, 2022 04.
Article in English | MEDLINE | ID: covidwho-1405274
ABSTRACT

INTRODUCTION:

Headache is a frequent adverse event after viral vaccines. We aimed to investigate the frequency and clinical associations of COVID-19 vaccine-related headache.

METHODS:

The characteristics, associations of this headache, main comorbidities, headache history following the influenza vaccine and during COVID-19 were investigated using a web-based questionnaire.

RESULTS:

A total of 1819 healthcare personnel (mean age 44.4 ± 13.4 years, 1222 females), vaccinated with inactivated virus, contributed to the survey; 209 (11.4%) had been infected with COVID-19. A total of 556 participants (30.6%) reported headache with significant female dominance (36.1% vs. 19.3%), 1.8 ± 3.5 (median 1; IQR 0-2) days following vaccination. One hundred and forty-four participants (25.9%) experienced headache lasting ≥3 days. Headache was mostly bilateral without accompanying phenomena, less severe, and shorter than COVID-19-related headache. The presence of primary headaches and migraine were significantly associated with COVID-19 vaccine-related headache (ORs = 2.16 [95% CI 1.74-2.68] and 1.65 [1.24-2.19], respectively). Headache during COVID-19 or following influenza vaccine also showed significant association with headache following COVID-19 vaccine (OR = 4.3 [95% CI 1.82-10.2] and OR = 4.84 [95% CI 2.84-8.23], respectively). Only thyroid diseases showed a significant association (OR = 1.54 [95% CI 1.15-2.08]) with vaccine-related headache among the common comorbidities.

CONCLUSION:

Headache is observed in 30.6% of the healthcare workers following COVID-19 vaccine and mostly experienced by females with pre-existing primary headaches, thyroid disorders, headache during COVID-19, or headache related to the influenza vaccine.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Adult / Female / Humans / Middle aged Language: English Journal: Cephalalgia Year: 2022 Document Type: Article Affiliation country: 03331024211042390

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Adult / Female / Humans / Middle aged Language: English Journal: Cephalalgia Year: 2022 Document Type: Article Affiliation country: 03331024211042390